Scientific SessionAbstracts(S7-2) Single Molecule Real-Time DNA Sequencingon the Surface <strong>of</strong> a Quantum-Dot NanocrystalP.B. Vander HornGenetic Systems, Life Technologies, Carlsbad, CA, UnitedStatesA single molecule, long read-length, real-time sequencingby-synthesistechnology has been developed by buildinga sequencer directly on the surface <strong>of</strong> a ~ 10 nm quantumdotnanocrystal. Fluorescence resonance energy-transfertechnology (FRET) is utilized for DNA sequence detection, inwhich signals from the quantum-dot labeled DNA polymeraseplus 4 DNA-base-specific acceptor dyes are simultaneouslydetected. Precisely engineered sequencing-grade Qdot TMnanocrystals are smaller than current commercially availablematerials (to increase FRET signals), and have an exctinctioncoefficient ~100X greater than organic-dyes, allowing for verylow levels <strong>of</strong> excitation power to be used while sequencing,Acting as the FRET donor, the Qdot TM -polymerase generates acorrelated “photon-dip” for every inserted based (termed the“quantum-correlation-signal”), allowing for more accurate basecalling.Because the sequencer is not physically bound to anysolid substrate, it can be exchanged (like a reagent) during midsequenceruns, effectively replacing damaged non-functioningpolymerases mid-reaction. Each exchange cycle lengthens theeffective read-length <strong>of</strong> the sequencer. In this manner, theread-length can be continuously extended without “gaps”.Expanding upon this flexibility, after sequencing a particularlength <strong>of</strong> DNA, the newly synthesized strand can be selectivelyremoved. The original genomic DNA strand is then re-primed,Qdot TM -polymerase sequencers are rebound, and the identicalgenomic DNA strand can be sequenced again, greatly increasingthe net accuracy and not requiring circularization <strong>of</strong> genomictemplates. In combining these features, the desired accuracyand read-length can be “tuned” by adjusting the number <strong>of</strong>reagent exchange cycles. Because each sequencing reaction canbe completed in minutes, multiple exchange experiments canbe performed per sequencing hour. These Qdot TM -polymerasesequencers can also bind to ultra-long DNA segments (>10kb)at multiple positions along the length <strong>of</strong> the DNA andsequence while moving “horizontally” (parallel to TIRF field),enabling the possibility <strong>of</strong> “ordered-reads” for long-phasedhaplotype sequencing. Examples <strong>of</strong> real-time sequencing <strong>of</strong>homopolymeric, patterned, and complex templates will beshown.(S9) Proteomics StandardizationD.B. FriedmanProteomics Laboratory Mass Spectrometry Research Center,Vanderbilt University, Nashville, TN, United StatesThe needs and issues related to establishing inter-laboratorystandardization in quantitative proteomics will be highlighted bypresentations from three international initiatives. By establishing theneed for standardization, each group will also highlight the tremendousamount <strong>of</strong> instrument and experimental variation that is also measuredwhen trying to determine real biological changes. The Spanish-basedProteoRed consortium addresses multiple proteomics platforms,ranging from MS-based to gel-based. The NIH CPTAC network isfocused on MS-based studies, and the UK-based FixingProteomicsinitiative covers mostly gel-based methods. Results from thesestudies will demonstrate complement and overlap in technology andapproaches used between these groups, all motivated by the universalgoal <strong>of</strong> standardizing these complex technologies across laboratories.(S9-1) A Multi-Laboratory Study AssessingRobustness and Reproducibility <strong>of</strong> PlasmaReference Sample for Benchmarking LC-MS PlatformPerformanceJ.P. Albar 5 , A. Campos 1,4 , E. Oliveira 1,4 ,S. Martínez-Bartolomé 3,4 , F. Canals 2,41Barcelona Science Park, Barcelona, Spain; 2 Vall d’HebronUniversity Hospital Research Institute, Barcelona, Spain;3Centro Nacional de Biotecnologia-CSIC, Madrid, Spain;4ProteoRed Consortium, Spanish National Institute <strong>of</strong>Proteomics, Madrid, Spain; 5 ProteoRed, National Center forBiotechnology-CSIC, Madrid, SpainAn increasingly common request for proteomics core facilities isdetermining qualitative and quantitative differences among clinicalsamples such as plasma, CSF, or urine. One <strong>of</strong> the missions <strong>of</strong> theSpanish Network <strong>of</strong> Proteomics Facilities (ProteoRed-ISCIII) is to assistits proteomics core facilities in evaluating their capabilities to performqualitative and quantitative proteomics analysis. This year, in an attemptto represent a realistic experiment scenario that might be requested toa proteomics core facility, we provided a moderately complex plasmastandard reference sample to be used for routine QC monitoring <strong>of</strong>laboratory instrumentation. The ProteoRed Plasma Reference (PPR)sample is a subset <strong>of</strong> highly abundant well-characterized human plasmaproteins with a number <strong>of</strong> is<strong>of</strong>orms, in addition to 4 spiked-in proteins,altogether distributed over 5 orders <strong>of</strong> magnitude in concentration.The PPR sample was recently stress tested in the latest ProteoRedMulticenter Experiment (PME6) that counted with the participation<strong>of</strong> 17 proteomics facilities using a wide range <strong>of</strong> LC-MS platforms. Werequested the sample be analyzed in a single LC-MS run in experimentaltriplicate (3 different digestions). Evaluation <strong>of</strong> the results submitted bythe study participants revealed moderate discrepancies at the peptideidentification level, and poor overlap at the protein identificationlevel. In an attempt to identify the source <strong>of</strong> such irreproducibility,raw data <strong>of</strong> 8 laboratories (24 LC-MS runs) were reanalyzed centrallyusing a standardized data analysis pipeline, which included proteininference using ProteinProphet s<strong>of</strong>tware. We found that the majority<strong>of</strong> protein identification discrepancies across submitted reports <strong>of</strong>these 8 laboratories were due to inconsistencies on how data analysisand computational tools group and/or infer proteins. Immunoglobulin42 • <strong>ABRF</strong> <strong>2011</strong> — Technologies to Enable Personalized Medicine
variable chain identifications were particularly conflicting throughoutidentification lists, even in the centralized analysis. Using a series <strong>of</strong>LC-MS performance metrics, we benchmarked the performance <strong>of</strong> 8LC-MS instruments (Orbitraps) and identified system components thatvary the most across laboratories.(S9-2) Clinical Proteomic Technologies for Cancer:NIH-Funded Measurement ScienceC.R. Kinsinger, E. Boja, T. Hiltke, M. Mesri, A. Rahbar,R. Rivers, H. RodriguezNational Cancer Institute, Center for Strategic ScientificInitiatives, Office <strong>of</strong> Cancer Clinical Proteomic Research,Bethesda, MD, United StatesIn 2006, the National Cancer Institute (NCI) launched the ClinicalProteomic Technologies for Cancer initiative (CPTC). The overallmission <strong>of</strong> this initiative was to foster the building <strong>of</strong> an integratedfoundation <strong>of</strong> proteomic technologies, data, analysis systems, andreagents and reference materials to systematically advance theapplication <strong>of</strong> protein science to accelerate discovery and clinicalresearch in cancer. Specifically, the CPTC was charged to addressissues <strong>of</strong> variability and irreproducibility in proteomic measurements.During the past five years, CPTC investigators have focused onassessing proteomic platforms involving mass spectrometry. Interlaboratorystudies have addressed variability in both unbiased andtargeted mass spectrometric methods. These studies have producedreference materials and data, performance metrics, standard operatingprocedures, and guidance for the community on the current ability<strong>of</strong> mass spectrometry for proteomics. Outputs from the technologyassessment aspects <strong>of</strong> CPTC have leveraged additional developments.First, CPTC inter-laboratory studies provided a basis for engaging theFDA on the metrological requirements for approval in vitro diagnosticmultivariateindex assays. Second, the NCI developed a follow-onfunding opportunity that applies the technology pipeline developedin the first phase <strong>of</strong> CPTC.(S9-3) Why Reproducible Outcomes are Essentialin Proteomic Research and Why Standardisation <strong>of</strong>Processes is Essential for Achieving ReproducibilityA. Borthwick, W. DracupNonlinear Dynamics, Newcastle upon Tyne, United KingdomIn both 2D electrophoresis and LC-MS proteomic analysis we are dealingwith highly complex samples, and there are many complex processesinvolved which in turn can be affected by a host <strong>of</strong> parameters and issuessuch as reagent batches, column performance, even the temperature <strong>of</strong>the lab. This complexity means that it can be very difficult to generatethe same results from the same samples in different labs and even inthe same lab at different times. This in turn makes it very difficult forlabs to build upon published results, a fundamental principle <strong>of</strong> thescientific method. Quality Control (QC), based on the use <strong>of</strong> standardsto monitor levels <strong>of</strong> technical variation in industrial processes isfundamental in the output <strong>of</strong> a reproducible product. We argue thatbecause proteomic analysis is significantly more challenging than mostindustrial processes, employing standards and the standardisation <strong>of</strong>processes in proteomics experiments is key to arriving at reproducibleoutcomes. Focusing mainly on 2D electrophoresis and to some extenton LC-MS we examine the importance <strong>of</strong> standardisation and howsuch standards may be applied to Proteomic research in order t<strong>of</strong>acilitate reproducible discoveries. Using studies carried out with singleand multi-users from within and between different laboratories, wedescribe our experiences <strong>of</strong> achieving standardisation using Standardsamples to provide feedback on the reproducibility <strong>of</strong> each stage andas well as the complete proteomic workflow.Scientific SessionAbstracts<strong>ABRF</strong> <strong>2011</strong> — Technologies to Enable Personalized Medicine • 43
- Page 7 and 8: Meeting SponsorsThe Association of
- Page 9 and 10: Registration ServicesRegistration S
- Page 12 and 13: Presenter InformationPresenter Info
- Page 14 and 15: AwardsABRF Annual Award for Outstan
- Page 16 and 17: ABRF Robert A. Welch Outstanding Re
- Page 18 and 19: Program-at-a-GlanceProgram-at-a-Gla
- Page 20 and 21: Sunday, February 20 (Continued)(S1-
- Page 22 and 23: Sunday, February 20 (Continued)(W3-
- Page 24 and 25: Monday, February 21 (Continued)12:0
- Page 26 and 27: Tuesday, February 22 (Continued)9:0
- Page 28 and 29: Tuesday, February 22 (Continued)(W1
- Page 30 and 31: Satellite Educational Workshop Spon
- Page 32 and 33: SW2: An Introduction to Metabolomic
- Page 34 and 35: SW4: Lean Management in Core Facili
- Page 36 and 37: Plenary Session AbstractsPlenary Se
- Page 38 and 39: Scientific Session AbstractsScienti
- Page 40 and 41: Scientific SessionAbstractsstatisti
- Page 42 and 43: Scientific SessionAbstracts(S5) Hig
- Page 46 and 47: Workshop Session AbstractsWorkshop
- Page 48 and 49: Workshop SessionAbstractscase incor
- Page 50 and 51: Workshop SessionAbstracts(W7) Cellu
- Page 52 and 53: Workshop SessionAbstractsresolution
- Page 54 and 55: (W14-3) Galaxy Next Generation Sequ
- Page 56 and 57: Research Group Presentation Abstrac
- Page 58 and 59: Research GroupPresentation Abstract
- Page 60 and 61: Research GroupPresentation Abstract
- Page 62 and 63: Poster Session Abstracts**ABRF Post
- Page 64 and 65: Poster Abstractsglobal gene express
- Page 66 and 67: Poster Abstractsdiscussions of cont
- Page 68 and 69: Poster Abstractspossible applicatio
- Page 70 and 71: Poster Abstracts129 Bravo Automated
- Page 73 and 74: distribution. Additionally, we show
- Page 75 and 76: Illumina Genome Analyzer. PicoPlex
- Page 77 and 78: uniformity, reproducibility of enri
- Page 79 and 80: kits for Tempus TM and PAXgene® st
- Page 81 and 82: 165 Benchmarking miRNA ExpressionLe
- Page 83 and 84: Phoenix crystallography robot and a
- Page 85 and 86: Laboratory is located next door and
- Page 87 and 88: data of a Thermo Orbitrap instrumen
- Page 89 and 90: **197 Multi-Functional Superparamag
- Page 91 and 92: pattern of N-linked glycans in form
- Page 93 and 94: advantage of using two separate 15
- Page 95 and 96:
allowed absolute quantitation. Comp
- Page 97 and 98:
levels between the animal groups. A
- Page 99 and 100:
MuDPIT, and off-gel electrophoresis
- Page 101 and 102:
237 Multi-Site Assessment of Proteo
- Page 103 and 104:
with good limits of quantification
- Page 105 and 106:
249 Rapid Monoclonal Antibody Glyca
- Page 107 and 108:
OOng, J. - 117PPatel, S. - 169Peake
- Page 109 and 110:
AnaSpec, Eurogentec Group Booth 417
- Page 111 and 112:
FASEB MARC Program Booth 4169650 Ro
- Page 113 and 114:
IntegenX, Inc. Booth 2015720 Stoner
- Page 115 and 116:
Nonlinear Dynamics Booth 1052530 Me
- Page 117 and 118:
Roche Applied Science Booth 5009115
- Page 119 and 120:
Exhibit Hall FloorplanGrand Oaks Ba
- Page 121 and 122:
Exhibitor List in Booth OrderExhibi
- Page 123 and 124:
This workshop will present ways to
- Page 125 and 126:
Grand Oaks Ballroom,Rooms P&Q, Leve
- Page 127 and 128:
NotesNotesABRF 2011 — Technologie
- Page 129 and 130:
Tuesday, February 22 — 12:00 pm -
- Page 131 and 132:
MARCH 16-20, 2012 • DISNEY’S CO